Studies with Combination Targeting Treatment in BRAF Mutated mCRC

Speaker: Chiara Cremolini

C. Cremolini discusses the characteristics of BRAF mutated metastatic colorectal cancer (mCRC) and the current challenges in the treatment of this subgroup. She digests results presented at ESMO World GI Congress 2015 with multiple targeting combinations, in particular combinations of MEK, BRAF and anti-EGFR inhibitors, either already approved for other cancers, or testing new agents in patients with advanced BRAF mutated CRC.

Discussion Points

  • Current standard for treatment of BRAF mutated metastatic colorectal cancer
  • Results of trametinib, dabrafenib and panitumumab in BRAF V600E mutated mCRC
  • Encorafenib in combination with cetuximab alone or cetuximab plus alpelisib for treatment of advanced BRAF-mutant CRC